scholarly journals Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation

2018 ◽  
Vol 184 (3) ◽  
pp. 479-483 ◽  
Author(s):  
Takashi Ishida ◽  
Tatsuro Jo ◽  
Shigeki Takemoto ◽  
Hitoshi Suzushima ◽  
Youko Suehiro ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Phase Ii Study ◽  
Haematopoietic Stem Cell ◽  
Cell Leukaemia ◽  
Newly Diagnosed

scholarly journals Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma

2003 ◽  
Vol 120 (2) ◽  
pp. 304-309 ◽  
Author(s):  
Masahiro Kami ◽  
Tamae Hamaki ◽  
Shigesaburo Miyakoshi ◽  
Naoko Murashige ◽  
Yoshinobu Kanda ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Cell Leukaemia

Immunological Evaluation after Haematopoietic Stem Cell Transplantation for B–Thalassemia Major

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4371-4371
Author(s):  
Marco Marziali ◽  
Antonella Isgro ◽  
Javid Gaziev ◽  
Daniela Fraboni ◽  
Paola Polchi ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Immune Reconstitution ◽  
Cd4 T Cell ◽  
Haematopoietic Stem Cell ◽  
The Mean

Abstract Background: Haematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with thalassemia. After HSCT is particularly important to recover a complete immune reconstitution for prevention of opportunistic infections. Methods: The immunological phenotype of peripheral blood mononuclear cells in 110 consecutively subjects after HLA identical HSCT performed for b thalassemia were studied. CD3+CD4+, CD3+CD8+, CD3−CD19+, CD3−CD16+CD56+ were evaluated by Flow Cytometry at 6 and 12 months after HSCT in 70 patients followed. In a part of patients CD4 naïve T cells was also evaluated at 12 months after HSCT. Results: at 6 months after HSCT we observed reduction of the mean of CD4 T cell percentage in patients respect normal value: in mean 17, 5 % ± 9 vs 45 % ± 10 respectively. After 1 year the rate of CD4+ T-cell population progressively increase: 24 ± 9 at 12 months vs 17, 5 % ± 9 at 6 months, but the mean of CD4+ T-cell count was persistently lower than in controls. The mean of CD8 T cell is stable during the follow up and the CD4/C8 ratio decreased. The mean of the CD19 increase during the follow up (4, 5 % at 6 months vs 17% at 12 months). At 1 year after HSCT the percentage of NK (CD3−CD16+CD56+) was normalized. At 1 year after HSCT reduction of naïve CD4 T cell we observed. Discussion. At 1 year after HSCT the immunological reconstitution is not still complete. The time and the extent of immune reconstitution depend on several factors. It is very important to continue the immune surveillance after HSTC and to evaluate other immunological parameters (i.e. thymic output) for to prevent infectious complications and elaborate an appropriate therapeutic strategy.

Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis

2019 ◽  
Vol 26 (11) ◽  
pp. 1351-1359 ◽  
Author(s):  
Diane Larsson ◽  
Torbjörn Åkerfeldt ◽  
Kristina Carlson ◽  
Joachim Burman
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Immunoglobulin Production ◽  
Neurofilament Light ◽  
Igg Index ◽  
Over Time

Background: Oligoclonal bands (OCB) are widely believed to be stable over time and rarely affected by disease-modifying treatment in MS. It is presently unknown how intrathecal immunoglobulin production and other cerebrospinal fluid (CSF) biomarkers are impacted by a highly efficacious procedure such as autologous haematopoietic stem cell transplantation (aHSCT). Objective: To describe the evolution of intrathecal immunoglobulin and neurofilament light (NFL) over time in MS patients treated with aHSCT. Methods: In this retrospective study, available data from previously made CSF investigations in 46 patients treated with aHSCT were analysed. Results: After a median follow-up time of 745 days, immunoglobulin G (IgG) OCB remained detectable in 74% of patients, the proportion of patients with a pathological IgG index went down from 70% to 46%, and the proportion of patients with a pathological NFL went down from 72% to 24%. In patients with follow-up time >1500 days, IgG OCB were detectable in 50% of patients, 14% had a pathological IgG index and none a pathological NFL. Conclusions: Intrathecal immunoglobulin production and NFL were lower after treatment with aHSCT, decreased over time and were normalised in a significant portion of patients. This challenges the notion that OCB are unaffected by therapeutic intervention in MS.

Sign in / Sign up

Export Citation Format

Share Document